Sangamo Therapeutics (SGMOQ) Return on Sales (2010 - 2025)

Sangamo Therapeutics' Return on Sales history runs 16 years deep, the most recent figure standing at 0.03% for Q4 2025.

• On a quarterly basis, Return on Sales rose 1.0% year-over-year to 0.03% in Q4 2025; TTM through Dec 2025 was 0.03%, a 1.0% decrease from a year earlier, with the FY2025 full-year figure at 0.03%, down 1.0% from the prior year.
• Return on Sales rose to 0.03% in Q4 2025 per SGMOQ's latest filing, from 0.6% in the prior quarter.
• Across five years, Return on Sales topped out at 0.0% in Q3 2024 and bottomed at 1.02% in Q1 2024.
• The 5-year median for Return on Sales is 0.02% (2022), against an average of 0.17%.
• Across the five-year window, Return on Sales slumped 102 bps in 2024 and jumped 100 bps in 2025, its largest moves.
• Year by year, Return on Sales stood at 0.01% in 2021, then tumbled by 42 bps to 0.02% in 2022, then slumped by 1448 bps to 0.3% in 2023, then jumped by 88 bps to 0.04% in 2024, then gained by 27 bps to 0.03% in 2025.
• Per Business Quant, the three latest SGMOQ Return on Sales figures stand at 0.03% (Q4 2025), 0.6% (Q3 2025), and 0.01% (Q2 2025).